We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
Read MoreHide Full Article
Catalent, Inc. (CTLT - Free Report) recently announced its collaboration with TFF Pharmaceuticals, Inc. (TFFP - Free Report) with respect to the latter’s patented Thin Film Freezing (“TFF”) technology. The tie-up agreement focuses on the generation, testing and manufacture of dry powder formulations for a variety of biotherapeutics via the application of the TFF technology.
Per the agreement terms, Catalent will offer its scaled-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner. This will enable Catalent to provide its customers access to the TFF technology.
The TFF technology can be used to generate dry powder formulations for inhalation. This complements Catalent’s existing capabilities in spray drying for the development of inhalable drugs, which was established by its 2021 buyout of the manufacturing and packaging operations of Acorda Therapeutics in Boston, MA.
The latest partnership is expected to solidify Catalent’s foothold in the global Oral and Specialty Delivery space.
Rationale Behind the Collaboration
The TFF technology has the potential to boost the adoption of the pulmonary route for systemic delivery of biotherapeutics. Thus, Catalent’s latest partnership regarding the technology is expected to enhance outcomes for its customers.
Catalent’s management believes that leveraging its expertise in the development and current good manufacturing practices or cGMP manufacture of dry powders will enable it to potentially bring TFF Pharmaceuticals’ unique and differentiated technology to scale.
Per TFF Pharmaceuticals’ management, the collaboration with Catalent is likely to significant expand its access to manufacturing capabilities and provide scalability for its technology. This simultaneously provides the company with the opportunity to build its portfolio of technology licensing partnerships.
Industry Prospects
Per a report by Transparency Market Research published on BioSpace, the global oral thin films market was valued at $2.6 billion in 2019 and is anticipated to expand at a CAGR of approximately 9% between 2020 and 2030. Factors like rise in demand for thin-film drug delivery systems and precision medication are likely to drive the market.
Given the market potential, the latest tie-up is expected to provide a significant boost to Catalent’s business globally.
Notable Developments
Last month, Catalent announced its plans to expand its Waigaoqiao Free Trade Zone facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies, as well as additional secondary packaging capabilities.
In January, the company announced that it has completed a $10-million expansion in its isolator units at its Malvern, PA and Dartford, U.K. facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.
The same month, Catalent launched its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies.
Price Performance
Shares of the company have lost 1.1% in the past year versus the industry’s 27% fall and the S&P 500's 13.4% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the broader medical space include Henry Schein, Inc. (HSIC - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
Henry Schein, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average beat being 25.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has gained 34.3% compared with the industry’s 12.2% growth over the past year.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average beat being 20%. It currently sports a Zacks Rank #1.
AMN Healthcare has gained 39.3% against the industry’s 54.9% fall over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
Catalent, Inc. (CTLT - Free Report) recently announced its collaboration with TFF Pharmaceuticals, Inc. (TFFP - Free Report) with respect to the latter’s patented Thin Film Freezing (“TFF”) technology. The tie-up agreement focuses on the generation, testing and manufacture of dry powder formulations for a variety of biotherapeutics via the application of the TFF technology.
Per the agreement terms, Catalent will offer its scaled-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner. This will enable Catalent to provide its customers access to the TFF technology.
The TFF technology can be used to generate dry powder formulations for inhalation. This complements Catalent’s existing capabilities in spray drying for the development of inhalable drugs, which was established by its 2021 buyout of the manufacturing and packaging operations of Acorda Therapeutics in Boston, MA.
The latest partnership is expected to solidify Catalent’s foothold in the global Oral and Specialty Delivery space.
Rationale Behind the Collaboration
The TFF technology has the potential to boost the adoption of the pulmonary route for systemic delivery of biotherapeutics. Thus, Catalent’s latest partnership regarding the technology is expected to enhance outcomes for its customers.
Catalent’s management believes that leveraging its expertise in the development and current good manufacturing practices or cGMP manufacture of dry powders will enable it to potentially bring TFF Pharmaceuticals’ unique and differentiated technology to scale.
Per TFF Pharmaceuticals’ management, the collaboration with Catalent is likely to significant expand its access to manufacturing capabilities and provide scalability for its technology. This simultaneously provides the company with the opportunity to build its portfolio of technology licensing partnerships.
Industry Prospects
Per a report by Transparency Market Research published on BioSpace, the global oral thin films market was valued at $2.6 billion in 2019 and is anticipated to expand at a CAGR of approximately 9% between 2020 and 2030. Factors like rise in demand for thin-film drug delivery systems and precision medication are likely to drive the market.
Given the market potential, the latest tie-up is expected to provide a significant boost to Catalent’s business globally.
Notable Developments
Last month, Catalent announced its plans to expand its Waigaoqiao Free Trade Zone facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies, as well as additional secondary packaging capabilities.
In January, the company announced that it has completed a $10-million expansion in its isolator units at its Malvern, PA and Dartford, U.K. facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.
The same month, Catalent launched its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies.
Price Performance
Shares of the company have lost 1.1% in the past year versus the industry’s 27% fall and the S&P 500's 13.4% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Catalent carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the broader medical space include Henry Schein, Inc. (HSIC - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
Henry Schein, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average beat being 25.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has gained 34.3% compared with the industry’s 12.2% growth over the past year.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average beat being 20%. It currently sports a Zacks Rank #1.
AMN Healthcare has gained 39.3% against the industry’s 54.9% fall over the past year.